Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

240 results about "Neurotoxicity" patented technology

Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an adverse effect on the structure or function of the central and/or peripheral nervous system. It occurs when exposure to substance – specifically, a neurotoxin – alters the normal activity of the nervous system in such a way as to cause permanent or reversible damage to nervous tissue. This can eventually disrupt or even kill neurons, which are cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from organ transplants, radiation treatment, certain drug therapies (e.g., substances used in chemotherapy), recreational drug use, and exposure to heavy metals, bites from certain species of venomous snakes, pesticides, certain industrial cleaning solvents, and certain naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness, loss of memory, vision, and/or intellect, uncontrollable obsessive and/or compulsive behaviors, delusions, headache, cognitive and behavioral problems and sexual dysfunction. Note there is strong evidence that chronic mold exposure in homes can lead to neurotoxicity which may not appear for months to years of exposure. All symptoms listed above are consistent with mold mycotoxin accumulation.

Recombinant live virus vector rabies vaccine without neurotoxicity

The invention discloses a neurotoxicity-free recombinant live virus vector rabies vaccine, which is prepared by replacing G protein of vesicular stomatitis virus with G protein of HEP-Flury rabies virus strain or G protein mutant of HEP-Flury rabies virus strain, and saving recombinant virus VSV-HEP-Flury by using a reverse genetic manipulation technology. The recombinant live virus vector rabies vaccine has no neurotoxicity after being inoculated. The method is free of neurotoxicity, high in safety, simple in inoculation procedure, good in immune effect and high in productivity.
Owner:HEFEI BAIYU BIOTECHNOLOGY CO LTD +1

Application of CD73 + NK cell in preparation of medicine for preventing or treating Parkinson's disease

The invention discloses an application of a CD73 + NK cell in preparation of a medicine for preventing or treating Parkinson's disease. The applicant discovers that the CD73 + NK cell can prevent dopaminergic neuron loss and glial inflammation response of the MPP + induced VM cell in the experimental process. However, TGF-beta1 and IL-10 secreted by the CD73 + NK cells do not significantly prevent loss of dopaminergic neurons induced by MPP + in cross-pore co-culture of the CD73 + NK cells and VM neurons. Therefore, the CD73 + NK cells are proved to protect dopaminergic neurons from the influence of MPP + neurotoxicity through an intercellular contact mechanism, namely CD73-SIRPA interaction.
Owner:SHENZHEN ZHONGJIA BIOMEDICAL TECH CO LTD

Thiamethoxam water dispersible granule and production process thereof

The invention provides thiamethoxam water dispersible granules and a production process thereof, and belongs to the technical field of pesticide preparation. The production process comprises the following steps: modifying methyl methacrylate; preparing an anti-ultraviolet carrier; loading eugenol; and preparing the water dispersible granules. The water dispersible granule is prepared by mixing the uvioresistant carrier loaded with eugenol with thiamethoxam, the dispersing agent, the wetting agent, the disintegrating agent and the binder, when eugenol and thiamethoxam are combined for use, the pest killing effect can be synergistically enhanced, and in addition, eugenol can bypass the resistance mechanism of pests to thiamethoxam, so that the pest killing effect is improved. Even if pests have certain tolerance to neurotoxicity of thiamethoxam, eugenol can still play a role by destroying cell membrane structures and respiratory systems of the pests, so that the resistance of the pests is broken, and the overall insecticidal effect of the prepared water dispersible granule is enhanced.
Owner:SHANDONG BAINONG SIDA BIOTECHNOLOGY CO LTD

Application of breast milk oligosaccharide in regulating brain immunity

The invention belongs to the technical field of food, and relates to application of breast milk oligosaccharide in regulating brain immunity. Specifically, the invention relates to the non-therapeutic purpose of adjusting brain immunity by adjusting polarization of microglial cells M1 / M2, and the breast milk oligosaccharide is any one of 3-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3 '-sialic acid lactose and 6'-sialic acid lactose. Research results show that a specific variety of breast milk oligosaccharides (especially 3-FL) can obviously inhibit the generation of neurotoxic factors NO, inflammatory factors TNF-alpha and IL-1beta in microglial cells, and promote the generation of anti-inflammatory cytokines IL-10 in the microglial cells, so that the state of the microglial cells is improved, damage repair is promoted, and the microglial cells are prevented from being damaged. Therefore, the effect of regulating brain immunity is achieved.
Owner:HEILONGJIANG FEIHE DAIRY CO LTD +1

Peptide with neuroprotective effect and application thereof

The invention belongs to the field of biological medicine, and particularly relates to a peptide with a neuroprotective effect and application thereof. The amino acid sequence of the polypeptide comprises an amino acid sequence P1-Linker-P2, and the polypeptide is a PSD-95 inhibitor, can atypically bind to the PDZ1 and / or PDZ2 structural domain of PSD-95 so as to inhibit the protein-protein interaction of the PDZ1 and / or PDZ2 structural domain with nNOS, and can be used for preparing drugs for treating excitatory neurotoxicity related injury.
Owner:HUNAN ZONSEN PEPLIB BIOTECH CO LTD

System and method for analyzing neurotoxicity of cyanobacteria toxin to aquatic organisms

The invention discloses a system and a method for analyzing neurotoxicity of cyanobacteria toxin to aquatic organisms, the system comprises a bottom plate, and also comprises an electric guide rail mechanism arranged on the bottom plate, and a bearing container mechanism arranged on a slide block of the electric guide rail mechanism; the first liquid feeding mechanism and the second liquid feeding mechanism are both arranged on the bottom plate; and the full-automatic fluorescent microscope is arranged on the bottom plate and located on the downstream of the second liquid feeding mechanism, an image acquisition module is arranged on an eyepiece of the full-automatic fluorescent microscope, and the image acquisition module is in communication connection with an analysis module. CYN solutions with different concentrations are injected into the placement groove through the first liquid feeding mechanism, a fixed solution is injected into the placement groove through the second liquid feeding mechanism, then the result of the influence of the CYN solutions with different concentrations on aquatic organisms is obtained through analysis of the full-automatic phosphor microscope, the image acquisition module and the analysis module, use is convenient, and the detection accuracy is high. And the labor intensity of workers is reduced.
Owner:NANJING INST OF ENVIRONMENTAL SCI MINIST OF ECOLOGY & ENVIRONMENT OF THE PEOPLES REPUBLIC OF CHINA

Application of compound for inhibiting phosphorylation of ARMC10 in preparation of medicine for antagonizing tin-induced nervous system injury

ActiveCN121606581AOrganic active ingredientsNervous disorderNervous systemMitochondrial Dynamic
The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.
Owner:ARMY MEDICAL UNIV

Phenolic diastereoisomer as well as preparation method and application thereof

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic diastereoisomer and a preparation method and application thereof.The phenolic diastereoisomer has the chemical structural formula shown in the formula I and the formula II, the formula I is dextroisomer and is named as (+)-fresh bamboo juice phenol D, and the formula II is levoisomer and is named as (-)-fresh bamboo juice phenol D. A pair of phenolic diastereoisomer compounds (+)-fresh bamboo juice phenol D and (-)-fresh bamboo juice phenol D are successfully obtained from fresh bamboo juice, and an anti-neurotoxicity activity test shows that (+)-fresh bamboo juice phenol D has a remarkable protection effect on PC12 cell injury caused by glutamic acid and can be used for preparing medicines for preventing or treating neurodegenerative diseases; wide application prospects are realized.
Owner:JIANGXI INST OF DRUG INSPECTION & TESTING

Lidocaine multivesicular liposome as well as preparation method and application thereof

PendingCN120346166AOrganic active ingredientsAntipyreticAnalgesics drugsAnalgesia postoperative
The invention relates to lidocaine multivesicular liposome as well as a preparation method and application thereof, belongs to the field of medicines, and solves at least one of the problems of higher toxicity, insufficient safety, short action time, limited clinical application range, higher cost and the like of the existing postoperative analgesic medicine. The lidocaine multi-vesicular liposome is prepared from lidocaine and a lipid, wherein the lidocaine and the lipid are added into the lidocaine multi-vesicular liposome; the lipid comprises amphiphilic lipid, negatively charged phospholipid, neutral lipid and cholesterol. The lidocaine multi-vesicular liposome prepared by the preparation method is high in safety, solves the problems of systemic toxicity, neurotoxicity, cardiotoxicity and the like of the existing postoperative analgesic drugs, has the characteristics of long-acting slow release, remarkable analgesic effect and wide clinical application range, and is suitable for clinical application. And a new solution is provided for effectively relieving postoperative pain.
Owner:PEKING UNIVERSITY THIRD HOSPITAL (THE THIRD CLINICAL MEDICAL SCHOOL OF PEKING UNIVERSITY)

Application of traditional Chinese medicine composition in preparation of medicine for relieving side effects of oxaliplatin chemotherapy

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV

Application of serratia marcescens in preparation of medicine for treating gradual freezing

The invention discloses an application of serratia marcescens in preparation of a medicine for preventing or treating gradual freezing (amyotrophic lateral sclerosis, ALS) or frontotemporal dementia (FTD). Specifically, the serratia marcescens of the present invention can improve the phenotype of an asymptomatic and frontotemporal dementia model S59L by reducing mitochondrial unfolded protein response (UPRmt); meanwhile, expression of excitatory amino acid glutamic acid can be reduced, excitatory neurotoxicity can be relieved, and ALS and FTD phenotypes can be relieved through cooperation of the two.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Method for regulating neurotoxic reactive astrocytes, regulator and application

TMEM164 and the like can prevent and inhibit the induced activation of neurotoxic reactive astrocytes and neuron death in neurodegenerative diseases. The present invention relates to the field of neuroscience, in particular the medical treatment of neurodegenerative diseases. TMEM164, SOC18, CAPN15 and the like are identified as early reaction regulatory factors of neurotoxic astrocyte reactivity, and it is found that for example, TMEM164 overexpression can prevent induced activation of neurotoxic reactive astrocytes and neuron death in mouse and human astrocytes, as well as in an inflammation-induced PD mouse model and a 5XFAD mouse model; therefore, a basis is provided for treatment of neurodegenerative diseases related to neurotoxic reactive astrocytes.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI

Pharmaceutical composition for treating Alzheimer's disease and preparation and detection methods thereof

The invention provides a pharmaceutical composition for treating Alzheimer's disease. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 10-15 parts of ginseng, 10-15 parts of rhizoma acori graminei, 10-15 parts of polygala tenuifolia, 15-20 parts of rhizoma polygonati, 15-20 parts of ginkgo leaves and 5-10 parts of schisandra chinensis. Therefore, the ginseng and the ginkgo leaves jointly regulate a cholinergic system and cerebral blood flow, and the cognitive function is enhanced; the rhizoma acori graminei and the ginkgo leaves cooperate to inhibit aggregation of beta-amyloid protein, improve cerebral circulation and relieve neurotoxicity. Polygonatum sibiricum and Chinese magnoliavine fruit protect nerve cells through anti-oxidation and anti-inflammatory effects and reduce nerve injury. Schizandrin further stabilizes a neurotransmitter system and enhances the synergistic effect of other medicinal materials, a multi-layer treatment network of Abeta deposition inhibition, cholinergic system regulation, anti-inflammation and anti-oxidation and nerve protection is integrally formed, and the core pathological link of the Alzheimer's disease is comprehensively intervened, so that the cognitive function is improved, and the disease progress is delayed.
Owner:SHAANXI XIZHOU PHARM CO LTD

Method for predicting peripheral neurotoxicity induced by treatment of colorectal cancer through oxaliplatin

The invention discloses a method for predicting peripheral neurotoxicity induced by treatment of colorectal cancer through oxaliplatin, and relates to the technical field of drug application, and the method comprises the following steps: obtaining pre-drug patient information before treatment of a patient with oxaliplatin and clinical feature data after use; processing and feature analysis are carried out based on pre-drug patient information and clinical feature data, and a core feature data set related to neurotoxin is determined; and based on the core feature data set, predicting the oxaliplatin-induced peripheral neurotoxicity of the patient by adopting a pre-trained gradient boosting decision tree model, and outputting a prediction risk result. According to the method, the occurrence risk of peripheral neurotoxicity can be accurately predicted according to clinical indexes so as to guide clinical accurate medication.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV

MDMA enantiomers

PCT designated stage expiredWO2024253775A1Nervous disorderHeterocyclic compound active ingredientsPhysical dependenceMDMA
A composition for use in psychotherapeutic or medical treatment of an R(-) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Owner:MIND MEDICINE INC

Wearable companion for detecting the cytokine release syndrome

Embodiments disclosed herein may provide digital medicine support for predicting and mitigating side effects of bispecific antibody treatment (e.g., Pfizer's Elranatamab) for myeloma patients. The side effects may include cytokine release syndrome (CRS), infection (e.g., sepsis), neurotoxicity (e.g., peripheral neuropathy), cytopenia (e.g., neutropenia), etc. These side effects may be predicted based on passive collection of data from patient wearables, patient entered data on healthcare application, and other data such as bloodwork data. Trained machine learning models may be used for predicting the side effects. As the side effects may be predicted before their onsets, a proactive intervention may be feasible to improve the healthcare outcomes for myeloma patients.
Owner:PFIZER INC

Engineered type e botulinum neurotoxin for therapeutic and cosmetic applications

PCT designated stage expiredWO2024206509A3Bacterial antigen ingredientsDepsipeptidesSV2ASerotype
Serotype E botulinum neurotoxin (BoNT / E) is one of the major causes of human botulism and paradoxically also a promising therapeutic agent. However, the molecular mechanism by which BoNT / E recognizes synaptic vesicle glycoprotein 2A (SV2.A) and 2B (SV2B), but no closely related SV2C, as its neuronal receptors has been challenging to resolve. The Inventor, surprisingly, was able to obtain crystal structures of the receptor-binding domain of BoNT / E (HCE) in complex with SV2.A. These structures reveal that HCE engages both specific peptide fragments and an N-glycan of SV2A, as well as SV2B in a similar manner. Structure-based mutagenesis and functional studies demonstrate that both the peptide- and glycan-based associations are essential for SV2A / 2B-mediated cell entry of BoNT / E and for its potent neurotoxicity. Thus, the engineering of BoNT / E variants for new clinical applications is described herein.
Owner:RGT UNIV OF CALIFORNIA

Long-acting solenopsis invicta killing bait and preparation method thereof

The invention relates to the field of solenopsis invicta prevention and control, in particular to a long-acting solenopsis invicta killing bait and a preparation method thereof.The long-acting solenopsis invicta killing bait is prepared from indoxacarb, sophocarpidine, huperzine A, piperidine, modified sodium alginate, corn, wheat, fructose, potassium sorbate, calcium propionate, vitamin E and modified glycerin. The insecticide components are prepared into microcapsules which wrap insecticidal active components and have a slow release effect, and the huperzine A inhibits acetylcholin esterase, increases the concentration of acetylcholine and activates a sodium ion channel; indoxacarb blocks a sodium ion channel and inhibits nerve impulse; the matrine inhibits Na < + >-ATPase and influences the membrane potential; the effects result in that nerve cells are more susceptible to indoxacarb. The modified sodium alginate changes the permeability of cell membranes and affects ion balance. Various components have a synergistic effect, so that the neurotoxicity is enhanced, the solenopsis invicta paralysis or death is finally caused, and the termite killing effect is improved. The long-acting bait combines efficient insect killing and environment friendliness, and an innovative solution is provided for prevention and control of the solenopsis invicta.
Owner:河南韩氏卫生用品科技有限公司

Toxicity-enhanced neurotoxin recombinant protein and application thereof

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.
Owner:NORTHWEST A & F UNIV

Intracranial drug balloon catheter and preparation method thereof

The invention belongs to the technical field of medical instruments, and particularly relates to an intracranial drug balloon catheter and a preparation method thereof. A two-time spraying method is adopted, the humidity of carrier gas during two-time spraying is controlled, an amorphous-state drug coating and a crystalline-state combined drug coating are formed on the surface of the balloon catheter, and the drug can be released, permeated and stored within 90 s after the balloon catheter adheres to the wall; further, the technical effects of effectively and lastingly inhibiting the intimal hyperplasia and reducing the restenosis rate are achieved, and the method has excellent trafficability and traceability and can adapt to the complex environment condition of intracranial tortuous blood vessels; meanwhile, the drug coating firmness and release performance can be achieved at the same time, and neurotoxic complications caused by drug falling during in vitro, delivery and expansion are avoided.
Owner:ZHEJIANG BELONGS TO A MEDICAL INSTR

Dihydrotriticale flavones, methods for their preparation and uses thereof

The present application relates to the technical field of medicine, and in particular to a dihydrotricin, a preparation method and use thereof, the preparation method comprising the following steps: taking compound A, diisopropylethylamine and bromomethyl methyl ether to prepare compound B; taking compound C, diisopropylethylamine and bromomethyl methyl ether to prepare compound D; taking compound B and compound D, adding sodium hydroxide to prepare compound E; taking compound E, adding hydrochloric acid to prepare dihydrotricin after washing, separation, and concentration. The preparation method realizes efficient and large-scale synthesis of dihydrotricin. It is first confirmed that dihydrotricin can significantly resist A 1‑42 Oligomer-induced neurotoxicity has broad prospects in preventing and treating middle and late AD and delaying the progression of AD.
Owner:SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Application of dehydrounionine in the preparation of drugs that reduce polymyxin toxicity

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.
Owner:CHINA AGRI UNIV

Pharmaceutical composition for treating pulmonary fibrosis complicated with depression and application thereof

The invention discloses a pharmaceutical composition for treating pulmonary fibrosis complicated with depression and application of the pharmaceutical composition, and belongs to the field of biological medicine. The pharmaceutical composition provided by the invention comprises harmine and deoxyvasicine, wherein the optimal mass ratio of harmine to deoxyvasicine is 1: 1.25. The curative effect of the pharmaceutical composition is verified by constructing a pulmonary fibrosis and depression combined mouse model, and experimental results show that the pharmaceutical composition provided by the invention can significantly improve the anti-fibrosis effect, can also effectively reduce the neurotoxicity of harmine, shows a synergistic effect, and can be used for preparing anti-fibrosis drugs for treating or preventing the fibrosis. And the curative effect and the safety are both improved. The invention lays a foundation for developing a safe and efficient novel medicine for treating pulmonary fibrosis combined with depression, and has important application value and wide application prospect in treatment of patients with pulmonary fibrosis combined with depression.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion

The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and / or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and / or neurotoxicity.
Owner:RICHARDSON PAUL G

Nasal injection type baicalein hydrogel as well as preparation method and application thereof

The invention discloses nasal injection type baicalein hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving carboxymethyl chitosan in water, stirring to form a uniform carboxymethyl chitosan solution, then adding a 4-formylphenylboronic acid / baicalein solution, and then continuously stirring until yellow transparent hydrogel is formed, namely the nasal injection type baicalein hydrogel is obtained. The hydrogel has self-healing ability and proper viscosity, can be adhered to the epithelium of the nasal cavity and is continuously released in the microenvironment of the nasal cavity, so that the brain entering efficiency of the baicalein is remarkably improved; neurotoxic oligomers formed by abnormal aggregation of alpha-syn can be reduced; neuroinflammation can be relieved by regulating and controlling phenotypic polarization of microglial cells M2; oxidative stress can be improved by removing excessive ROS, dopaminergic neuron apoptosis is reduced, and the compound can be used for treating Parkinson's disease and has a good application prospect.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Compositions for treating neurodegenerative diseases and methods thereof

Disclosed herein are compounds and methods of use thereof effective for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells in the brain and spinal cord, eventually causing loss of muscle strength. The compounds of the disclosure include, cutamesine, a synthetic sigma receptor agonist selective for the 81 receptor, and also a chaperone protein of the central nervous system that plays a key role in the modulation of calcium ions and apoptosis, as well as a sapogenin, such as smilagenin, a non-peptide neurotrophic factor that aids in the reversal of free radical neurotoxicity.
Owner:RAYA THERAPEUTIC INC

Method for screening key neurotoxic substances in food raw materials and their products by combining caenorhabditis elegans model with metabolomics

PendingCN122345603ABiotechnologyFood material
This invention discloses a method for screening key neurotoxic substances in food raw materials and their products using a *C. elegans* model combined with metabolomics. Food samples are processed to prepare a stock solution, which is then used to cultivate *C. elegans*. The sample exhibiting the greatest neurotoxicity to the nematodes is identified by analyzing the number of *C. elegans* movements and neuronal fluorescence images. Subsequently, key neurotoxic substances in food are systematically screened using a combination of non-targeted liquid chromatography-tandem mass spectrometry (LC-MS / MS) and a metabolomics platform. This application establishes a novel method for screening neurotoxic substances by combining nematode activity with non-targeted LC-MS / MS determination and a non-targeted metabolic platform, clarifying key neurotoxic substances in food and providing a theoretical basis for food quality control and high-quality development.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Pharmaceutical composition for preventing or treating degenerative brain diseases, comprising prasugrel as active ingredient

PCT designated stageWO2025159459A1Organic active ingredientsNervous disorderMicroglial cell activationBULK ACTIVE INGREDIENT
The present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases, the composition comprising prasugrel as an active ingredient. The composition containing prasugrel or a salt thereof according to the present invention has excellent neuroprotective activity and, in particular, can suppress MPP+-induced neurotoxicity and neuronal cell death, suppress LPS-induced microglial cell activation and cell migration, and has neuroinflammation inhibitory activity, and thus has the effect of preventing, alleviating, and treating various degenerative brain diseases including Parkinson's disease.
Owner:DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

A photosensitizer targeting beta amyloid and its preparation method and application

The application discloses a photosensitizer targeting beta amyloid, and a preparation method and application thereof. The photosensitizer is a photosensitizer with A-D-A configuration, and a structural formula thereof is shown as formula I. The photosensitizer synthesized in the application has a longer emission wavelength, and after being combined with beta amyloid, the fluorescence signal is obviously enhanced, and can effectively generate singlet oxygen, that is, the photosensitizer can target mark A beta protein, and is used for fluorescence imaging of the A beta protein; and after the photosensitizer synthesized in the application is combined with beta amyloid in the brain of an Alzheimer's disease (AD) model mouse, the cognitive ability of the AD mouse can be effectively improved, A beta-mediated neurotoxicity can be reduced, and clearance of A beta plaques can be promoted, that is, the photosensitizer can be used for early diagnosis and treatment of Alzheimer's disease.
Owner:SOUTH CHINA UNIV OF TECH

Application of PAD4 inhibitor to preparation of medicine for preventing and treating peripheral neuropathy caused by chemotherapy medicine

The invention provides application of a PAD4 inhibitor to preparation of a medicine for preventing and treating peripheral nerve injury caused by chemotherapy medicines. Experiments find that the PAD4 inhibitor has a protective effect on peripheral nerve cell toxicity caused by chemotherapeutic drugs, and particularly has a protective effect on neurotoxicity of ND7 / 23 cells induced by oxaliplatin; on an animal model, the PAD4 inhibitor has a protective effect on oxaliplatin-induced mouse peripheral neurotoxicity. The PAD4 inhibitor can be used as an adjuvant of a chemotherapeutic drug for cancer treatment, and has an effect of relieving neurotoxicity caused by chemotherapy.
Owner:NANJING UNIV OF TRADITIONAL CHINESE MEDICINE +1